See All Slides - tctmd.com

Slides

Presentation THT 2026

Keeping Patients out of DanGer

Presenter: Jacob Eifer Moeller

March 03, 2026

Presentation THT 2026

Barostimulation Therapy for HFrEF

Presenter: Philip Adamson, MD

March 03, 2026

Presentation THT 2026

Central Venous Congestion in Transcatheter Tricuspid Repair: Lessons from the TRI.Fr Trial

Presenter: Karl-Philipp Rommel

March 03, 2026

Presentation THT 2026

Atrial Shunt for Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes from the REDUCE LAP-HF II Trial

Presenter: Sanjiv J. Shah

March 03, 2026

Presentation THT 2026

Defining the Targets for Gene Therapy and Optimizing Vectors for Delivery

Presenter: Roger J. Hajjar

March 03, 2026

Presentation THT 2026

Medication Regimen Changes and Clinical Outcomes in the Cardiac Microcurrent (C-MIC) II Randomized Trial

Presenter: Marat Fudim

March 03, 2026

Presentation THT 2026

The Lymphatic System as a Target for ADHF

Presenter: Jan Biegus

March 03, 2026

Presentation THT 2026

Artificial Intelligence Meets Real-World Heart Failure: Early Results from the HF-TRACK Trial

Presenter: Shamus Husheer

March 03, 2026

Presentation THT 2026

Reducing Renal Venous Pressure to Improve Urine Output: Overview of Devices, Current Status, and Future Directions

Presenter: Arvind Bhimaraj

March 03, 2026

Presentation THT 2026

Incidence of HF Therapy Escalation and Time-to-Clinical Worsening in Atrial Shunt- vs. Sham-Treated Patients with HFpEF/HFmrEF During 5-Year Follow-Up: REDUCE LAP-HF II Trial

Presenter: Grant Reed

March 03, 2026

Advertisement

Slides

Keeping Patients out of DanGer

Barostimulation Therapy for HFrEF

Central Venous Congestion in Transcatheter Tricuspid Repair: Lessons from the TRI.Fr Trial

Atrial Shunt for Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes from the REDUCE LAP-HF II Trial

Defining the Targets for Gene Therapy and Optimizing Vectors for Delivery

Medication Regimen Changes and Clinical Outcomes in the Cardiac Microcurrent (C-MIC) II Randomized Trial

The Lymphatic System as a Target for ADHF

Artificial Intelligence Meets Real-World Heart Failure: Early Results from the HF-TRACK Trial

Reducing Renal Venous Pressure to Improve Urine Output: Overview of Devices, Current Status, and Future Directions

Incidence of HF Therapy Escalation and Time-to-Clinical Worsening in Atrial Shunt- vs. Sham-Treated Patients with HFpEF/HFmrEF During 5-Year Follow-Up: REDUCE LAP-HF II Trial

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content